Xilio Therapeutics Inc - XLO STOCK NEWS

Xilio Therapeutics, Inc. announces strategic portfolio reprioritization to focus on clinical-stage programs for XTX301 and XTX101, additional Phase 2 data for XTX202, and a private placement with gross proceeds of $11.3 million. The company also entered into an exclusive license agreement with Gilead Sciences, Inc., anticipating up to $604.0 million in additional contingent payments.

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have entered into an exclusive license agreement for Xilio's Phase 1 tumor-activated IL-12 program, XTX301, to treat various cancers. XTX301 is currently in a Phase 1 trial for advanced solid tumors. The agreement includes upfront payments of $43.5 million, potential additional payments of up to $604.0 million, and royalties on global sales. Gilead may transition to lead development after specified clinical data delivery, with a $75 million fee. However, the transaction is expected to reduce Gilead's 2024 EPS by $0.03 - $0.04.

Xilio Therapeutics, Inc. announced René Russo's participation in the 'Novel Immuno-Oncology' panel discussion at the TD Cowen 44th Annual Health Care Conference. The event will take place on March 4, 2024, at 10:30 am EST, with a live webcast available on the company's website.

Xilio Therapeutics, Inc. announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The company focuses on discovering and developing tumor-activated immuno-oncology therapies for cancer patients. The event will be live webcasted and accessible through the company's website, with a replay available for 30 days.

Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company reporting encouraging preliminary safety data from the first three dose levels of XTX301, a tumor-activated IL-12, in patients with advanced solid tumors. The company has also initiated patient dosing in Phase 1/2 trial for XTX101 and plans to report Phase 2 trial data for XTX202 by the end of the first quarter of 2024.

Xilio Therapeutics, Inc. (XLO) announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology (IO) refractory solid tumors. The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023. The Phase 1 combination dose escalation is expected to support a planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC). The updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consistent with tumor-activated molecule design, and a 33% disease control rate across a range of late-line and IO refractory advanced solid tumors. The company also reported a confirmed partial response with XTX101 monotherapy in a patient with advanced PD-L1 negative NSCLC continued through 36 weeks, including complete resolution of liver metastases.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced pipeline progress and business updates, including the initial clinical validation of tumor-selective activation technology for XTX101 and XTX202. The company reported a 50% disease control rate at higher doses for XTX202 and plans to evaluate XTX202 as monotherapy. Xilio also anticipates reporting preliminary Phase 1 safety data for XTX301 in the fourth quarter of 2023.

Xilio Therapeutics, a clinical-stage biotechnology company, announced initial safety and efficacy data from its Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in patients with advanced solid tumors. The trial showed a disease control rate of 50% at higher doses (≥2.8 mg/kg) and 31% across all dose levels. Treatment-related adverse events were primarily Grade 1-2, with no signs of vascular leak syndrome reported. Two patients continued treatment for more than 1 year. Xilio plans to evaluate XTX202 as a monotherapy in a Phase 2 trial for advanced melanoma and renal cell carcinoma.

Xilio Therapeutics, Inc. will host an investor conference call and webcast on November 6, 2023, to review progress across its pipeline of tumor-activated molecules. The call will feature the presentation of Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, at the SITC 38th Annual Meeting. The webcast can be accessed on the company's website.